BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $2,878,275 | -49.4% | 38,796 | -43.4% | 0.01% | -53.6% |
| Q4 2022 | $5,683,579 | +16.6% | 68,576 | +299.4% | 0.03% | +12.0% |
| Q3 2022 | $4,876,000 | +18.9% | 17,168 | +45.1% | 0.02% | +25.0% |
| Q2 2022 | $4,101,000 | +11.3% | 11,831 | +39.0% | 0.02% | +42.9% |
| Q1 2022 | $3,686,000 | -14.3% | 8,511 | +2.4% | 0.01% | -12.5% |
| Q4 2021 | $4,300,000 | +9.6% | 8,311 | +2.7% | 0.02% | -11.1% |
| Q3 2021 | $3,922,000 | +31.1% | 8,093 | +21.8% | 0.02% | +38.5% |
| Q2 2021 | $2,991,000 | +32.5% | 6,642 | +12.4% | 0.01% | +30.0% |
| Q1 2021 | $2,257,000 | +46.8% | 5,909 | +22.1% | 0.01% | +42.9% |
| Q4 2020 | $1,537,000 | +18.8% | 4,839 | -7.3% | 0.01% | +16.7% |
| Q3 2020 | $1,294,000 | -4.1% | 5,222 | +2.1% | 0.01% | 0.0% |
| Q2 2020 | $1,350,000 | +47.1% | 5,114 | +5.7% | 0.01% | 0.0% |
| Q1 2020 | $918,000 | -13.6% | 4,839 | 0.0% | 0.01% | +20.0% |
| Q4 2019 | $1,062,000 | -51.6% | 4,839 | -56.8% | 0.01% | -58.3% |
| Q3 2019 | $2,194,000 | -6.2% | 11,212 | 0.0% | 0.01% | -7.7% |
| Q2 2019 | $2,338,000 | -8.3% | 11,212 | -12.7% | 0.01% | -7.1% |
| Q1 2019 | $2,550,000 | +53.1% | 12,842 | +11.6% | 0.01% | +40.0% |
| Q4 2018 | $1,666,000 | -29.1% | 11,512 | 0.0% | 0.01% | -16.7% |
| Q3 2018 | $2,350,000 | +47.8% | 11,512 | +7.1% | 0.01% | +33.3% |
| Q2 2018 | $1,590,000 | -2.1% | 10,750 | 0.0% | 0.01% | 0.0% |
| Q1 2018 | $1,624,000 | -74.0% | 10,750 | -77.7% | 0.01% | -73.5% |
| Q4 2017 | $6,245,000 | +7.2% | 48,208 | 0.0% | 0.03% | 0.0% |
| Q3 2017 | $5,828,000 | +2.9% | 48,208 | 0.0% | 0.03% | -5.6% |
| Q2 2017 | $5,664,000 | +79.5% | 48,208 | +55.3% | 0.04% | +56.5% |
| Q1 2017 | $3,156,000 | +79.9% | 31,050 | +82.0% | 0.02% | +64.3% |
| Q4 2016 | $1,754,000 | -6.1% | 17,062 | 0.0% | 0.01% | -12.5% |
| Q3 2016 | $1,868,000 | -3.5% | 17,062 | -0.6% | 0.02% | 0.0% |
| Q2 2016 | $1,935,000 | -1.4% | 17,162 | -17.4% | 0.02% | -11.1% |
| Q1 2016 | $1,963,000 | +4.5% | 20,772 | -0.5% | 0.02% | +5.9% |
| Q4 2015 | $1,878,000 | -31.4% | 20,872 | -29.5% | 0.02% | -37.0% |
| Q3 2015 | $2,736,000 | -16.3% | 29,590 | -10.8% | 0.03% | -10.0% |
| Q2 2015 | $3,268,000 | -1.8% | 33,190 | 0.0% | 0.03% | -3.2% |
| Q1 2015 | $3,329,000 | +14.3% | 33,190 | +5.3% | 0.03% | +14.8% |
| Q4 2014 | $2,912,000 | – | 31,510 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |